摘要
孤儿药的定价和报销关系到患者用药的可及性,对罕见病的防治与保障具有重要意义。欧洲国家在孤儿药医保准入过程中形成了卫生技术评估的特殊标准和路径,并建立了专项支付基金和多样化的风险分担协议,有效地提升了孤儿药的可及性。基于此,文章选取欧洲典型国家,对比分析其孤儿药定价和报销的主要特点和共性保障思路,提出“构建孤儿药卫生技术评估加速程序、探索医保外孤儿药的分类保障机制、通过孤儿药定价和调整实现供给及研发的激励机制”的建议,以期为优化我国孤儿药市场准入机制提供参考依据。
The pricing and reimbursement of orphan drugs are related to the accessibility of patients,and are of great significance to the prevention and guarantee of rare diseases.European countries have formed special standards and paths for health technology evaluation,and established special payment funds and diversified risk-sharing agreements,which have effectively improved the accessibility of orphan drugs.Based on this,it selected typical European countries to compare the orphan drug pricing and reimbursement methods.Then,it put forward some suggestions“building orphan drug health technology evaluation accelerated program,exploring the health of orphan drug classification security mechanism,and attaining supply incentives and development incentives through orphan drug pricing and adjustment”,to optimize the basis for the orphan drug market access mechanism to provide reference.
作者
杨伊凡
谢金平
闫丽羽
翁婷婷
邵蓉
Yang Yifan;Xie Jinping;Yan Liyu(The Research Center of National Drug Policy and Ecosystem,China Pharmaceutical University,Nanjing,211198,China)
出处
《中国卫生经济》
北大核心
2024年第2期92-96,共5页
Chinese Health Economics
基金
江苏省研究生科研创新计划“供应链协同理论下我国孤儿药供应保障体系优化研究”(KYCX23_0884)。
关键词
罕见病
孤儿药
定价和报销
欧洲
卫生技术评估
rare disease
orphan drug
pricing and reimbursement
Europe
health technology assessment
